Vaxcyte, Inc. — Director's Dealing 2026

Mar 3, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2026-02-26

Reporting Person: GUGGENHIME ANDREW (PRESIDENT AND CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-26	Common Stock	A	44864	—	Acquired	107323	Direct
2026-02-28	Common Stock	F	898	$61.98	Disposed	106425	Direct
2026-03-02	Common Stock	F	1009	$61.98	Disposed	105416	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-26	Stock Option (right to buy)	$60	A	74993	Acquired	2036-02-26	Common Stock (74993)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	61850	Indirect

Footnotes

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The
RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through
each such date.

F2: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

F3: Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.

F4: 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.